Anti-
6,6′-dihydroxythiobinupharidine (DTBN)
Leishmania major
Nuphar lutea
anti-Leishmania small molecule
cutaneous leishmaniasis
Journal
Pathogens (Basel, Switzerland)
ISSN: 2076-0817
Titre abrégé: Pathogens
Pays: Switzerland
ID NLM: 101596317
Informations de publication
Date de publication:
06 May 2024
06 May 2024
Historique:
received:
25
03
2024
revised:
30
04
2024
accepted:
03
05
2024
medline:
24
5
2024
pubmed:
24
5
2024
entrez:
24
5
2024
Statut:
epublish
Résumé
Cutaneous leishmaniasis (CL) is a zoonotic disease, manifested as chronic ulcers, potentially leaving unattractive scars. There is no preventive vaccination or optimal medication against leishmaniasis. Chemotherapy generally depends upon a small group of compounds, each with its own efficacy, toxicity, and rate of drug resistance. To date, no standardized, simple, safe, and highly effective regimen for treating CL exists. Therefore, there is an urgent need to develop new optimal medication for this disease. Sesquiterpen thio-alkaloids constitute a group of plant secondary metabolites that bear great potential for medicinal uses. The nupharidines found in
Identifiants
pubmed: 38787236
pii: pathogens13050384
doi: 10.3390/pathogens13050384
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Israel Ministry of Health
ID : 3-0-7374